Q-omics provides the consensus-scored ENTPD1 profile across patient tissues and cancer cell-line models. ENTPD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ENTPD1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ENTPD1 protein abundance shows 26,179 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where ENTPD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENTPD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENTPD1 survival associations across molecular data types. ENTPD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENTPD1 RNA expression–survival associations across cancer types. High ENTPD1 expression shows unfavorable associations in ACC, but favorable associations in HNSC, KIRC, LUAD, SKCM and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ENTPD1 RNA expression.
This table summarizes ENTPD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ENTPD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENTPD1 shows lower tumor expression in BLCA and KICH and higher tumor expression in KIRC, HNSC, THCA and LIHC. The KIRC box plot shows higher ENTPD1 RNA expression in tumor versus normal tissue (log2 FC = +1.189, t-test p < 0.001).
This table shows molecular features associated with ENTPD1 in patient tissues and cancer cell lines. In patient samples, ENTPD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ENTPD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
